Position your brand around unmet needs that compounded products cannot reliably addresssuch as clinical consistency, long-term safety, and regulatory assurance
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
The 503A pathway remains the primary current legal route for individual patient-specific compounded GLP-1 prescriptions, subject to clinical documentation requirements
Tips for Getting the Most Out of Your L-Carnitine Once you know how to take L-Carnitine liquid, optimizing your routine ensures even better results
We need prospective studies that stratify GLP-1 agonist outcomes by baseline endogenous hormone levels, something no major clinical trial has done
Sandrin L, Tanter M, Gennisson JL, et al